Engineering S. typhimurium for metastatic colorectal cancer
工程鼠伤寒沙门氏菌治疗转移性结直肠癌
基本信息
- 批准号:9973552
- 负责人:
- 金额:$ 34.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-15 至 2024-09-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAnimal ModelAnimalsAntitumor ResponseAttenuatedAutomobile DrivingBacteriaBiological AssayCD47 geneCD8B1 geneCancer BiologyCancer ModelCell DeathCell LineCellsClinicalClinical TrialsCoculture TechniquesColorectalColorectal CancerCombined Modality TherapyCommunitiesCuesCytolysisDatabasesDevelopmentDiagnosticDiseaseEngineeringEnvironmentEuthanasiaEvaluationFluorescence MicroscopyFutureGenesGeneticGenetic EngineeringGenetic ProgrammingGoalsGrowthHeterogeneityHistologicHome environmentHomingHumanHuman bodyHypoxiaImmunologic SurveillanceImmunotherapeutic agentInfiltrationIntelligenceLibrariesLiverMalignant NeoplasmsMetastatic Neoplasm to the LiverMicrobeMicroscopyModelingMolecularMusNecrosisNeoplasm MetastasisOralOrganPathogenicityPeptidesPerformancePopulationPrevalenceProductionReporterResearchRouteSafetySalmonella typhimuriumSolid NeoplasmSourceSpecificitySystemTestingTherapeuticTimeToxic effectToxinTreatment EfficacyTumor Tissueanti-canceranti-cancer therapeuticattenuationbasecancer therapycell typeclinical translationcolorectal cancer treatmentcytotoxicitydraining lymph nodeeffective therapyeffector T cellefficacy studyimmunogenicityimprovedin vivo imaging systeminterestlead candidatemetastatic colorectalmicrobiome researchmouse modelnovelnovel therapeuticspreclinical toxicityresponsesafety studysafety testingscreeningspatiotemporalsynergismsynthetic biologytherapeutic evaluationtherapy outcometime usetooltumortumor growthtumor hypoxiatumor microenvironmentvector
项目摘要
The engineering of living cells and microbes is driving a new era of cancer therapy. This transformative approach
allows for the genetic programming of living cells to intelligently sense and respond to environments, ultimately
adding specificity and efficacy that is otherwise unattainable with molecular-based therapeutics. Due to recent
microbiome studies indicating the prevalence of bacteria within the human body and specifically in tumor tissue,
bacteria have generated significant interest as cancer therapies. Additionally, a multitude of empirical studies
have demonstrated that administered bacteria home and selectively grow in tumors due to reduced immune
surveillance of tumor cores. Given their presence and selectivity for tumors, bacteria present a unique oppor-
tunity to be engineered as intelligent delivery vehicles for cancer therapy.
The objective of this proposal is to engineer and optimize S. typhimurium for metastatic colorectal cancer
therapy. Since animal based-testing regimes limit the rate of clinical progress, we will use a high-throughput,
bacteria-spheroid platform to rapidly test therapeutic payloads and production and release strategies. We will
also assess the effect of therapies on colorectal genetic backgrounds, and investigate spatio-temporal hetero-
geneity in 3D spheroids with the use of engineered cell reporters. We will then test lead candidates in mouse
models of primary and metastatic colorectal cancer to evaluate safety and efficacy. We will focus on colorectal
cancer due to several proof-of-concept studies from our lab demonstrating efficacy in colorectal spheroids and
animal models. In particular, we showed that oral delivery of bacteria can specifically colonize colorectal liver
metastases, providing an attractive delivery route as a cancer therapy. Since these metastases are often con-
fined to the liver, this approach can have a significant impact on tumor growth and survival. The research in this
proposal will help to establish a framework to genetically engineer microbes for cancer therapy, and significantly
accelerates tools that will impact the broader cancer and synthetic biology communities. If successful, future
lead candidates for potential clinical trials will be identified on the basis of therapeutic efficacy and safety studies
from this proposal.
活细胞和微生物工程正在推动癌症治疗的新时代。这种变革的方法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tal Danino其他文献
Tal Danino的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tal Danino', 18)}}的其他基金
Engineering probiotics for tuberculosis therapy
用于结核病治疗的工程益生菌
- 批准号:
10511520 - 财政年份:2022
- 资助金额:
$ 34.67万 - 项目类别:
Engineering probiotics for tuberculosis therapy
用于结核病治疗的工程益生菌
- 批准号:
10629371 - 财政年份:2022
- 资助金额:
$ 34.67万 - 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
- 批准号:
10034374 - 财政年份:2020
- 资助金额:
$ 34.67万 - 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
- 批准号:
10681319 - 财政年份:2020
- 资助金额:
$ 34.67万 - 项目类别:
Engineering immunotherapeutic probiotics to mitigate irAE
工程免疫治疗益生菌以减轻 irAE
- 批准号:
10378953 - 财政年份:2020
- 资助金额:
$ 34.67万 - 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
- 批准号:
10447144 - 财政年份:2020
- 资助金额:
$ 34.67万 - 项目类别:
Probiotic guided CAR-T therapy (ProCARs) for breast cancer
益生菌引导的乳腺癌 CAR-T 疗法 (ProCAR)
- 批准号:
10263960 - 财政年份:2020
- 资助金额:
$ 34.67万 - 项目类别:
Engineering S. typhimurium for metastatic colorectal cancer
工程鼠伤寒沙门氏菌治疗转移性结直肠癌
- 批准号:
10532672 - 财政年份:2020
- 资助金额:
$ 34.67万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 34.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists